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Abstract
Background: It remains unclear whether patients with positive surgical margins or extra-
capsular extension benefit from adjuvant radiotherapy following radical prostatectomy.
Objective: To compare the effectiveness and tolerability of adjuvant radiotherapy
following radical prostatectomy.
Design, setting, and participants: This was a randomised, open-label, parallel-group
trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight
Finnish hospitals, with pT2 with positive margins or pT3a, pN0, M0 cancer without
seminal vesicle invasion.
Intervention: A total of 126 patients received adjuvant radiotherapy at 66.6 Gy.
Outcome measurements and statistical analysis: The primary endpoint was biochemi-
cal recurrence-free survival, whichwe analysed using the Kaplan-Meiermethod and Cox
proportional hazard regression. Overall survival, cancer-speciﬁc survival, local recur-
rence, and adverse events were secondary endpoints.
Results and limitations: The median follow-up time for patients who were alive when
the follow-up ended was 9.3 yr in the adjuvant group and 8.6 yr in the observation
ivagroup. The 10-yr surv* Corresponding author. [9_TD$DIFF] Cancer Gene Therapy Group, University of Helsinki, Haartmaninkatu 3,
00290 Helsinki, Finland. Tel. +358 294 125 464.
emminki@helsinki.fi (A. Hemminki).E-mail address: akseli.hhttps://doi.org/10.1016/j.eururo.2019.07.001
0302-2838/© 2019 European Association of Urology. Published by Elsevierl for biochemical recurrence was 82% in the adjuvant group andB.V. All rights reserved.
61% in the observation group (hazard ratio [HR] 0.26 [95% conﬁdence interval {CI} 0.14–
0.48], p < 0.001), and for overall survival 92% and 87%, respectively (HR 0.69 [95% CI
0.29–1.60], p = 0.4). Two and four metastatic cancers occurred, respectively. Out of the
43 patients with biochemical recurrence in the observation group, 37 patients received
salvage radiotherapy. In the adjuvant group, 56% experienced grade 3 adverse events,
versus 40% in the observation group (p = 0.016). Only one grade 4 adverse event occurred
(adjuvant group). A limitation of this study was the number of patients.
Conclusions: Adjuvant radiotherapy following radical prostatectomy is generally well
tolerated and prolongs biochemical recurrence-free survival compared with radical
prostatectomy alone in patients with positive margins or extracapsular extension.
Patient summary: Radiotherapy given immediately after prostate cancer surgery pro-
longs prostate-speciﬁc antigen progression-free survival, but causes more adverse
events, when compared with surgery alone.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
E U RO P E AN URO L OGY 76 ( 2 019 ) 5 8 6 – 5 9 5 5871. Introduction
Curative therapies for clinically localised cT1–2 prostate
cancer include radical prostatectomy and radiotherapy,
while in locally advanced cT3–4 prostate cancer, there is a
lack of general consensus on the risk-benefit ratios of
various treatment options [1,2]. The impact of positive
surgical margins on survival in localised pT2 after radical
prostatectomy is controversial and dependent on other
tumour characteristics [3]. Following radical prostatectomy,
positive margins or extracapsular extension (pT3–4) are
considered independent risk factors for biochemical recur-
rence [4]. Locally advanced pT3 disease associates with an
increased risk of recurrence,metastasis, and prostate cancer
death [4,5]. In a multinational study of >20 000 radical
prostatectomy patients, Sooriakumaran et al. [6] reported
14–23% positive margins and 23–38% pT3 disease, depend-
ing on the surgical technique.
Currently, there is no consensus on the optimal
treatment for patients whose disease is pT2 with positive
margins or pT3 with/without positive margins, following
prostatectomywith curative intent. If these patients benefit
from radiotherapy, the question is whether they should
receive irradiation in the form of immediate, adjuvant
radiotherapy or as salvage radiotherapy given at prostate-
specific antigen (PSA) recurrence. The latest guidelines
suggest adjuvant radiotherapy or observation following
prostatectomy for patients with adverse pathologic findings
such as positive surgical margins, seminal vesicle invasion,
and/or extracapsular extension [7,8].
Three earlier randomised studies compared adjuvant
radiotherapy with observation in radical prostatectomy
patients: Southwest Oncology Group (SWOG 8794), Euro-
pean Organization for Research and Treatment of Cancer
(EORTC 22911), and German Cancer Society (ARO 96-02/
AUO AP 09/95), all of which included pT3 patients with
positive margins [9–11]. In addition, EORTC included pT2
patients with positive margins [10]. Adjuvant radiotherapy
compared favourably with observation regarding PSA
relapse-free survival in all the studies [9–11]. Only SWOG
found benefit in metastasis-free and overall survival [9]. Of
note, the majority of events were unrelated to prostate
cancer.
While the prior randomised trials have predominantly
focused on pT3–4 prostate cancer (with/without positivemargins), the design of this study asks whether patients
with pT2N0M0 (with positive margins) and pT3aN0M0
(regardless of margins) benefit from adjuvant radiotherapy
following radical prostatectomy.
2. Patients and methods
This is a randomised, open-label, parallel-group, multicentre, collabora-
tive study of FinnProstate and Finnish Radiation Oncology Groups
(NCT02668718). The Surgical Ethics Committee of Hospital District of
Helsinki and Uusimaa evaluated the trial protocol and informed consent
form. The trial was performed according to the principles of Declaration
of Helsinki. Data are reported on an intent-to-treat basis.
We randomised 250 patients (1:1), with the hypothesis that 80% in
the adjuvant group and 60% in the observation group will remain
biochemical progression free after 2 yr of follow-up, giving a power of
80% and signiﬁcance level of 5%. As calculated by Fischer’s exact test,
the required sample size for two independent groups was 90 patients/
group. To avoid loss of power due to possible loss in follow-up,
investigators writing the protocol decided to increase the sample size to
125 patients/group (39% safety margin) based on clinical judgement and
experience from previous prostate cancer trials.
The inclusion criteria included written informed consent, pT2N0M0
with a positive margin or pT3aN0M0 (with/without positive margins)
prostate cancer, Gleason score 2–10, preoperative PSA 20mg/l, and
postoperative PSA <0.5mg/l.
The exclusion criteria included other concurrent cancer therapy
including systemic endocrine therapy, more than 12 wk since radical
prostatectomy, metastatic disease (N+ or M1), and invasion of seminal
vesicles.
Following the patient’s informed consent, the urologist called Finnish
Cancer Registry (Helsinki, Finland), which conducted stratiﬁcation into
three groups by Gleason score (Gleason scores 2–6, 7, and 8–10) and
randomisation.
The radiation dose consisted of 66.6 Gygiven in 37 fractions of 1.8 Gy/
d, 5 d perweek. Patients received three-dimensional conformal radiation
therapy (with linear accelerator >10 MV) without pelvic lymph node
irradiation.
The protocol deﬁned progression as (1) PSA >0.4 mg/l in two
successive measurements at least 4 wk apart, (2) metastatic prostate
cancer, or (3) recurrent prostate cancer in imaging regardless of PSA. In
the observation group, salvage radiotherapy could be offered upon
disease progression.
We graded adverse events from patients’ individual medical records
from randomisation to progression or until the last follow-up if the
patient was progression free. At visits (between 0 and 51 mo from radical
prostatectomy), patients ﬁlled three questionnaires: (1) International
Index of Erectile Function (IIEF-5), (2) International Prostate Symptom
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Objective, Management, Analytic (LENT-SOMA) questionnaire with
intestinal and urinary questions from the subjective, objective, and
management parts of the LENT-SOMA parameters.
We used the Kaplan-Meiermethod to calculate 10-yr survival rates for
biochemical recurrence-free, overall, prostate cancer-speciﬁc, metastatic,
and castration-resistant prostate cancer (CRPC)-free survival. To test
survival difference between the adjuvant and the observation group, we
used Cox proportional hazard regression analysis for hazard ratios (HRs)
with 95% conﬁdence intervals (CIs), and for p values. In addition, we used
multivariable Cox regression to test (1) the association between
biochemical recurrence and group after adjusting for preoperative PSA,[(Fig._1)TD$FIG]Fig. 1 – Flow chart. Protocol-defined progression = (1) PSA >0.4mg/l in two suc
or (3) recurrent prostate cancer in imaging regardless of PSA. The median tim
11.7 wk (range 7.6–30, interquartile range 11–12.6). Five patients had interrupt
adverse effects, one had viral infection with fever, one had cholecystitis, and f
the dose to 63 Gy due to grade 2 faecal frequency. The other four patients rece
PSA = prostate-specific antigen.Gleasonscore (Gleason scores5–6, 7, and8–9), andpTstage (pT2,pT3), and
(2) the interaction between preoperative PSA and the treatment group
regarding biochemical recurrence. Patients were censored at the time of
deﬁned event or last follow-up. We used SPSS for the aforementioned
analyses (IBM SPSS Statistics for Windows, version 25.0; IBM Corp.,
Armonk, NY, USA).
We used generalised linear mixedmodel with lmer function (GLMM)
to compare groups (adjuvant and observation) regarding the number of
patients experiencing adverse events and the total number of adverse
events. In both models, we modelled all adverse events regardless of the
grade. We used binary response (any adverse event regardless of the
grade vs no adverse event) for adverse events experienced by thecessive measurements at least 4 wk apart, (2) metastatic prostate cancer,
e from radical prostatectomy to initiation of adjuvant radiotherapy was
ions of adjuvant radiotherapy, two suffered from urinary/intestinal
or one patient the reason was unavailable. One patient decided to limit
ived the planned total dose of 66.6 Gy.
Table 1 – Patient characteristics (number of patients) at
randomisation in the adjuvant radiotherapy and observation
groups
Adjuvant Observation
Patients 126 124
Age (yr)
Median (interquartile
range)
61 (57–65) 62 (59–65)
Gleason score
5 9 8
6 29 25
7 81 83
8 4 4
9 3 4
ISUP grade[8_TD$DIFF] group
1 38 33
2 53 59
3 26 21
4 4 4
5 3 4
Unavailable 2 3
cT
1 4 2
1a 2 1
1c 62 66
2 17 26
2a 2 1
2b 2 0
3 1 3
3a 1 0
Unavailable 35 25
pT
2 1 0
2a 10 13
2b 10 11
2c 52 39
3a 53 59
4 0 1
Unavailable 0 1
Preoperative PSA (mg/l)
<20 125 123
>20a 1 1
Median (interquartile
range)
7.2 (5.2–10.1) 7.5 (5.5–10.2)
Postoperative PSA (mg/l)b
<0.05 24 35
<0.1 14 9
<0.2 20 20
<0.4 33 22
<0.5 35 37
0.5 0 1
ISUP = International Society of Urological Pathology; PSA = prostate-
speciﬁc antigen.
a Preoperative PSA was 21.9 mg/l for one patient in the adjuvant
radiotherapy group and 22.2 mg/l for one patient in the observation group.
b Postoperative PSA corresponds to study entry PSA and PSA at the
beginning of radiotherapy. Between randomisation and the beginning of
adjuvant radiation, none of the patients met the criteria for biochemical
progression.
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distribution. In both models, a group (observation vs adjuvant) was
modelled as a ﬁxed effect. Patients constituted potential sources of
variation, and therefore this subject-speciﬁc effect was included as a
random effect in the model [12].
In addition, we used a binary response to model severe erectile
dysfunction (IIEF-5 scores 1–7 vs 8–25) and severe urinary symptoms
(IPSS scores 20–35 vs 0–19) over follow-up time using GLMM to compare
groups (adjuvant and observation). Similarly, we used a binary response
to model the severity of LENT-SOMA urinary and intestinal toxicities
(grade 3–4 vs 1–2). In these four models, explanatory variables (group
and time in months) were modelled as ﬁxed effects, and patient-speciﬁc
effect as a random effect. Time was treated as a continuous variable. The
GLMMwas appliedwith the R statistical software package (version 3.5.2,
lme4[11_TD$DIFF] function, R Core Team [2018]. R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna,
Austria. URL https://www.R-project.org/).
Our primary endpoint was biochemical recurrence-free survival.
Overall survival, cancer-speciﬁc survival, local recurrence, and adverse
events were secondary endpoints. Metastatic and castration-resistant
survival analyses were unplanned. We measured all survival analyses
and follow-up from radical prostatectomy.
3. Results
A total of 250 patients enrolled in the trial (Fig. 1) between
April 2004 and October 2012 at eight regional Finnish
hospitals (listed in the Supplementary material), and the
follow-up ended in January 2017. Patient characteristics are
given in Table 1. Protocol violations are in listed in
Supplementary Table 1.
3.1. Overall, prostate cancer-specific, and metastatic-free
survival
The median follow-up time for patients who were alive
when the follow-up ended was 9.3 yr (range 3.3–12.6,
interquartile range [IQR] 6.5–10.3) in the adjuvant group
and 8.6 yr (range 3.6–12.1, IQR 6.4–10.4) in the observation
group. The 10-yr overall survival was 92% in the adjuvant
group and 87% in the observation group (HR 0.69 [95% CI
0.29–1.60], p = 0.4). Only two patients died of prostate
cancer, one in each group (Fig. 2 and Table 2). The 10-yr
prostate cancer-specific survival was 99% in both groups
(HR 1.00 [95% CI 0.06–15.91], p = 1).
The 10-yr metastatic-free survival was 98% in the
adjuvant group and 96% in the observation group (HR
0.49 [95% CI 0.09–2.68], p = 0.4). The 10-yr CRPC-free
survival was 96% and 92%, respectively (HR 0.50 [95% CI
0.12–1.88], p = 0.3).
3.2. Biochemical recurrence and second-line treatments
The 10-yr biochemical recurrence-free survival was 82% in
the adjuvant group and 61% in the observation group (HR
0.26 [95% CI 0.14–0.48], p < 0.001). When adjusted for
preoperative PSA, Gleason score, and pT stage, the HR for
biochemical recurrence for adjuvant versus observation
group was 0.30 (95% CI 0.16–0.54, p < 0.001). The number
needed to treat was 4. The median follow-up time for
biochemical recurrence-free patients was 8.6 yr in theadjuvant group and 8.2 yr in the observation group. We
present the median preoperative PSA for patients with/
without biochemical recurrence in Supplementary Table 2.
In the adjuvant group, three of 73 patients with pT2
disease and positive surgical margins experienced protocol-
defined biochemical recurrence compared with 21 of 63 in
the observation group. For pT3 patients, the numbers were
12/53 and 22/59, respectively. For Gleason score 5–6
[(Fig._2)TD$FIG]
Fig. 2 – Crude Cox proportional hazard regression for biochemical recurrence-free, overall, prostate cancer-specific, and metastatic-free survival in the
adjuvant radiotherapy and the observation group. (A) Biochemical recurrence-fee survival. (B) Overall survival. (C) Prostate cancer-specific survival. (D)
Metastasis-free survival.
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protocol-defined biochemical recurrence compared with
12 of 33 in the observation group. For Gleason score 7, the
numbers were 11 of 81 and 29 of 83 patients, respectively.
In the adjuvant group, 12 patients received androgen
deprivation as second-line treatment (median PSA 1.4mg/l,
range 0.44–32, IQR 0.78–5.7) and three were under activesurveillance after protocol-defined progression (Fig. 1). Out
of the 43 patients with protocol-defined biochemical
recurrence in the observation group, 37 received salvage
radiotherapy within a median of 20 wk (range 4.6–152, IQR
12–33) from progression (median PSA 0.7 mg/l, range 0.42–
8.2, IQR 0.57–0.83; Supplementary Fig. 1). PSA was
measured a median of 4.7 wk (range 0–12, IQR 1.1–7.5)
Table 2 – Main results for the adjuvant radiotherapy versus the observation group: number of patients experiencing protocol-defined
biochemical recurrence, metastatic prostate cancer, castration-resistant prostate cancer, prostate cancer death, and death from any causea
Adjuvant
(n = 126)
Observation
(n = 124)
HR, 95% CI p value
Biochemical recurrenceb 15 43 0.30, 0.16–0.53 <0.001
Metastatic 2 4 0.49, 0.09–2.68 0.4
Castration resistantc 3 6 0.47, 0.12–1.88 0.3
Prostate cancer deathd 1 1 1.00, 0.06–15.91 1
Death from any cause 10 13 0.76, 0.33–1.72 0.5
CI = conﬁdence interval; HR = hazard ratio; PSA = prostate-speciﬁc antigen.
a Separate univariable Cox proportional hazard regression analysis was used showing results by HRs with 95% CIs, and p values, associated with receiving
adjuvant radiotherapy versus observation.
b We detected no local recurrence with imaging, and all patients diagnosed with metastases experienced biochemical progression before metastases were
detected.
c Castration-resistant cancer was defined as consecutively increasing PSA in two successive measurements at least 4 wk apart despite androgen deprivation
therapy.
d These patients both had Gleason 7 (4 + 3) prostate cancer; they died 6.7 and 6.5 yr after prostatectomy at the age of 62 and 53 yr with metastatic-free survival of
2.8 and 2.3 yr (adjuvant radiotherapy and observation group, respectively). For the other four patients with metastases, the range of metastatic-free survival was
4–8.6 yr.
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active surveillance (Fig. 1). Following salvage radiotherapy,
28 patients achieved PSA remission, while nine required
systemic therapies.
In addition, 10 patients received salvage radiotherapy
for biochemical recurrence that did not meet the
protocol’s criteria for progression, with a median PSA
value of 0.4 mg/l (range 0.12–0.53, IQR 0.18–0.43; Fig. 1
and Supplementary Table 1). One was from the adjuvant
group, but had declined adjuvant radiotherapy, while
nine were from the observation group. Of these
10 patients, all except one (from the observation group)
achieved PSA remission. Additionally, one patient in the
observation group, with no PSA progression or metasta-
ses, received hormonal therapies.
3.3. Toxicity
The most common grade 3 adverse events were erectile
dysfunction (37% of adjuvant and 28% of observation
patients) and urinary incontinence (12% and 5%, respec-
tively; Table 3). One grade 4 adverse event, a compartment
syndrome, occurred in the adjuvant group. This was a
postoperative complication of cystectomy occurring nearly
7 yr after radical prostatectomy. Prior to cystectomy, the
patient suffered from incontinence following transurethral
incision of the vesicourethral anastomosis done due to
urinary retention, a postoperative complication of ventral
hernia repair. There were no grade 5 adverse events.
IIEF-5, IPSS, and LENT-SOMA results are given in Fig. 3.
4. Discussion
There was a clear statistically significant difference in
biochemical recurrence-free survival, which is in accor-
dance with earlier findings [9–11]. The most notable
differences were seen among patients with (1) pT2 disease
and positive margins, and (2) Gleason scores 5–6.A lack of conclusive results from randomised trials
comparing adjuvant radiotherapy and observation, fear of
toxicity, and avoidance of “overtreatment” have promoted
active surveillance and early salvage irradiation, resulting in
low use of adjuvant radiotherapy even in patients with
adverse pathologic features [13]. Results from retrospective
studies comparing adjuvant radiotherapy and early salvage
radiation are controversial, while results from several on-
going randomised trials (RADICALS and RAVES) are not
available yet [14–16].
When comparing early and late salvage radiotherapy
following radical prostatectomy, the observational data
support improved efficacy with early irradiation [17]. The
common definition for early and late salvage radiation is
PSA 0.5 mg/l and PSA >0.5mg/l, respectively [17]. Since in
this trial salvage radiotherapy in the observation group was
given at a median PSA of 0.7mg/l, this would be considered
as late salvage, although it was lower comparedwith SWOG,
EORTC, andARO,which had themedian PSA levels of 0.75–1,
1.7, and 1.7 mg/l, respectively [9–11].
According to contemporary standards, the enrolment
criteria for postoperative PSA would have been <0.2mg/l,
compared with our threshold of PSA <0.5mg/l, which was
standard when the trial was designed. However, 46% of
patients in the adjuvant group and 52% in the observation
group had preoperative PSA <0.2mg/l.
In addition, at the initiation of this trial, a common
threshold for biochemical recurrence was PSA >0.4mg/l,
which was therefore applied in this protocol. However, due
to more accurate testing, currently PSA 0.2 mg/l is
frequently used, which explains why some patients in this
trial received second-line therapywith PSA levels<0.4mg/l.
Compared with this study, the other three randomised
trials included patients with slightly more adverse
features. In SWOG, 33% had seminal vesicle invasion alone
or together with positive margins and extracapsular
extension, and 15% had postoperative PSA 0.2 mg/l
[9]. In EORTC, 25% had seminal vesicle invasion, and 30%
Table 3 – Number (and proportion) of patients in the adjuvant radiotherapy and the observation group experiencing adverse events, scored
from patients’ individual medical records, and the three most common disordersa,b,c
Adjuvant (N = 126) Observation (N = 124) Univariable observation vs
adjuvant (any adverse event
regardless of the grade)d
n (%) n (%) p value OR 95% CI
Number of patients experiencing adverse event 0.009e 0.71 (0.55–0.92)
Grade 1 121 (96) 105 (85)
Grade 2 115 (91) 107 (87)
Grade 3 70 (56) 50 (40)
Grade 4 1 (1) 0 (0)
Number of patients experiencing gastrointestinal disorders <0.001e 0.12 (0.07–0.19)
Grade 1 97 (77) 16 (13)
Grade 2 29 (23) 4 (3)
Grade 3 1 (1) 1 (1)
Grade 4 0 (0) 0 (0)
Number of patients experiencing urinary disorders <0.001e 0.48 (0.36–0.64)
Grade 1 111 (88) 77 (62)
Grade 2 72 (57) 47 (38)
Grade 3 18 (14) 7 (6)
Grade 4 0 (0) 0 (0)
Number of patients experiencing erectile dysfunction 0.050e 0.75 (0.56–1.00)
Grade 1 71 (56) 52 (42)
Grade 2 94 (75) 95 (77)
Grade 3 47 (37) 35 (28)
Grade 4 0 (0) 0 (0)
Total number of adverse events <0.001f
Grade 1 733 259
Grade 2 298 165
Grade 3 105 62
Grade 4 1 0
Total 1137 486
Median and range of adverse events per patient
Grade 1 6 (0–17) 1.5 (0–11)
Grade 2 2 (0–14) 1 (0–4)
Grade 3 1 (0–6) 0 (0–3)
Grade 4 0 (0–1) –
CI = conﬁdence interval; OR = odds ratio PSA = prostate-speciﬁc antigen.
a Adverse events were scored from individual medical records using Common Toxicity Criteria for Adverse Events version 4.03. The scoring of adverse events
began from randomisation and ended when progression occurred or at the end of the follow-up time if the patient was PSA progression free. We included all
adverse events; that is, the relation between the adverse event and the trial treatment was not evaluated.
b Two patients (one from each group) experienced no adverse event.
c Patients with grade 3 urinary incontinence required surgical treatment including transurethral injection, urethrotomy, sling, and artificial urinary sphincter.
Twelve patients in the adjuvant group and three in the observation group suffered grade 3 urethral stricture, which needed surgical intervention. For grade
3 inguinal hernia requiring surgical intervention, the numbers were 8 and 9, respectively.
d Univariable generalised linear mixed model:
e binomial (any adverse event regardless of the grade vs no grade) and
f Poisson distribution. In both models, group (observation vs adjuvant) was modelled as a fixed effect and patients as a random effect.
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>pT3a cancer [11]. The aforementioned adverse features
are often considered an indication for adjuvant radiother-
apy. For example, 80–86% of patients with seminal vesicle
invasion suffer from PSA recurrence [18,19]. Hence, we
excluded these patients.
In a subgroup analysis of EORTC, positive surgical
margins and age <70 yr were associated with greater
benefit from adjuvant radiotherapy [10]. In ARO, patients
with positive surgical margins benefitted most from
adjuvant radiotherapy [11]. SWOG reported no subgroups
that benefitted significantly from adjuvant radiotherapy [9].
There were significantly more adverse events in the
adjuvant group, as expected, although most of these were
grade 1–2 and transient. The findings were similarregarding patient-reported toxicities (LENT-SOMA), al-
though the patients reported more grade 3–4 LENT-SOMA
toxicities than Common Terminology Criteria for Adverse
Events (CTCAE, version 4.03). When comparing the toxicity
grading used in this study, LENT-SOMA had a tendency for
higher grades compared with CTCAE. Depending on the
time of visit, a median of 86 (range 18–105) patients in the
adjuvant group and a median of 71 (range 28–94) patients
in the observation group filled the LENT-SOMA question-
naire (Fig. 3). The compliance rate of patient-reported
outcomes often declines towards the end of the trial
[20,21]. We detected no trends between treatment groups
or hospitals regarding the compliance rate.
Following radical prostatectomy, the 10-yr overall
survival varies from 72% to 87% in different studies
[(Fig._3)TD$FIG]
Fig. 3 – (A) International Index of Erectile Function (IIEF-5), (B) International Prostate Symptom Score (IPSS), and maximum Late Effects Normal Tissue
Task Force—Subjective, Objective, Management, Analytic (LENT-SOMA) grade for (C) urinary and (D) intestinal toxicities measured from radical
prostatectomy and presented separately for the adjuvant radiotherapy and the observation group as predicted probabilities using a generalised linear
mixed model (GLMM). (A) Severity of erectile dysfunction. Predicted probabilities of IIEF-5 shown separately for the adjuvant and the observation
group. Effect of treatment group (observation vs adjuvant; OR 0.70 [95% CI 0.29–1.68], p = 0.4) and time[7_TD$DIFF] in months (OR 0.97 [95% CI 0.95–0.99],
p = 0.002), and interaction of group and time (OR 0.98 [95% CI 0.95–1.00], p = 0.047) for severe dysfunction (IIEF-5 score was modelled as binomially
distributed scores 1–7 vs 8–25) over continuous time (months) according to GLMM. IIEF-5 score: 1–7 = severe erectile dysfunction, 8–21 = mild-
moderate erectile dysfunction, and 22–25 = no erectile dysfunction. (B) Severity of urinary symptoms. Predicted probabilities of IPSS shown separately
for the adjuvant and the observation group. Effect of treatment group (observation vs adjuvant; OR 0.51 [95% CI 0.25–1.03], p = 0.061) and time [7_TD$DIFF] in
months (OR 0.96 [95% CI 0.95–0.98], p < 0.001) for severe dysfunction (IPSS score was modelled as binomially distributed scores 20–35 vs 0–19) over
continuous time (months) according to GLMM. IPSS score: 0–7 = mild urinary symptoms, 8–19 = moderate urinary symptoms, and 20–35 = severe
urinary symptoms. (C) Maximum LENT-SOMA grade for each patient, urinary toxicities. Predicted probabilities of LENT-SOMA grades shown separately
for the adjuvant and the observation group. Effect of treatment group (observation vs adjuvant; OR 0.76 [95% CI 0.40–1.42], p = 0.4) and time[7_TD$DIFF] in
months (OR 0.99 [95% CI 0.97–1.00], p = 0.064) for severe grades (urinary toxicities were modelled as binomially distributed grades 3–4 vs 0–2) over
continuous time (months) according to GLMM. (D) Maximum LENT-SOMA grade for each patient, intestinal toxicities. Predicted probabilities of LENT-
SOMA grades shown separately for the adjuvant and the observation group. Effect of treatment group (observation vs adjuvant; OR 0.04 [95% CI 0.00–
0.43], p = 0.008), time[7_TD$DIFF] in months (OR 0.97 [95% CI 0.94–1.01], p = 0.1), and interaction (OR 1.10 [95% CI 1.03–1.18], p = 0.006) for severe grades (LENT-
SOMA modelled as binomially distributed grades 3–4 vs 0–2) over continuous time (months) according to GLMM. The LENT-SOMA toxicities were
graded according to the patients’ answers from 0 to 4, where grade 0 stands for no toxicity and grade 4 stands for the most severe toxicity. For one
LENT-SOMA question regarding the management of dysuria, the answer option for surgical intervention (grade 4 toxicity) was unavailable; therefore,
the answers for this question were graded from 1 to 3. The most common LENT-SOMA toxicities were urinary frequency (93% of the patients in the
adjuvant group and 92% in the observation group filled the questionnaire), urinary incontinence (70% and 62%, respectively), decreased urinary stream
(61% and 56%, respectively), and rectal tenesmus (64% and 42%, respectively). The most common grade 4 toxicities were kidney-related toxicity
(18 patients in the adjuvant group and 15 in the observation group), urinary incontinence (seven and five patients, respectively), and urinary frequency
(five and two patients, respectively). The most common grade 4 kidney-related toxicity was based on two questions: answering “yes” to “do you suffer
from tiredness and headache?” led to grade 3, and “yes” to “are you passing less urine than you usually do/are your feet swollen?” led to grade
4 toxicity. 95% CI = 95% confidence interval; OR = odds ratio.
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E U RO P E AN U RO LOGY 76 ( 2 019 ) 5 8 6 – 5 9 5594[22,23]. Metastatic disease and thus prostate cancer death
can occur long after biochemical recurrence, suggesting that
considerably longer follow-up time would be required to
detect any survival benefit.
5. Conclusions
In summary, adjuvant radiotherapy prolongs the time from
radical prostatectomy to biochemical recurrence with the
strongest impact on pT2 disease with positive margins and
Gleason score 5–7. However, adjuvant radiotherapy causes
more adverse effects compared with observation, and
salvage therapy upon biochemical recurrence appears as
effective as adjuvant therapywith regard to overall survival.
In the observation arm, 37 of 124 patients received salvage
radiotherapy for protocol-defined progression, after which
28 remained recurrence free, while 121 of 126 patients in
the adjuvant arm received radiotherapy following radical
prostatectomy (five declined radiation despite randomisa-
tion into this arm). Of note, more cases ofmetastatic disease
and CRPC occurred in the observation (“salvage”) arm,
suggesting that high-risk patients should be offered the
possibility to consider adjuvant radiotherapy following
radical prostatectomy. Only the patient can balance the
subjective questions of radiation-related adverse events to a
lower risk of biochemical recurrence, cancer progression,
and its consequences.
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